Top 10 Companies in Microbubbles/Ultrasound Contrast Agents Market

The Microbubbles/Ultrasound Contrast Agents Market is expected to grow at a CAGR of 25.2% from 2018 to 2024 to reach USD 1,584.5 million by 2024. Microbubbles are small spherical bubbles comprised of three phases namely innermost gas phase, shell material enclosing the gas phase, and outermost gas or liquid phase. The field of ultrasound contrast imaging has been literally bursting since the last decade. The advancement in ultrasound technologies over the last decade have resulted in widespread usage of ultrasound contrast imaging for clinical applications. This technology is preferred by most researchers due to low-cost, convenience, and real-time capability.

Here are the top 10 companies operating in the Microbubbles/Ultrasound Contrast Agents Market 

Lantheus Holdings, Inc. (U.S.)

Founded in 1956 and headquartered at Massachusetts, U.S.; Lantheus Holdings, Inc. is engaged in providing medical imaging solutions by manufacturing diagnostic image agents and products through its subsidiary namely Lantheus Medical Imaging, Inc.

With its subsidiaries and strong network of distribution, the company has its presence in North America, Europe, Asia Pacific, and Latin America. The subsidiaries of the company are Lantheus Medical Imaging, Inc., Lantheus MI Canada, Inc., Lantheus MI Radiopharmaceuticals, Inc., Lantheus MI UK Limited, J.B. Chemicals and Pharmaceuticals Ltd, and Lantheus MI Real Estate, LLC.

Bracco (Italy)

Established in 1927 and headquartered in Milan, Italy; Bracco is an international Group active in the healthcare sector and diagnostic imaging. The company is engaged mainly in providing contrast agents, medical substances for improving the diagnostic accuracy of biomedical imaging, and the care of patients affected by diseases of varying type and severity.

The company offers contrast agents under its subsidiary, Bracco Imaging S.p.A. With its subsidiaries and strong network of distributors, Bracco Imaging S.p.A. has its production facility in Italy, Canada, Switzerland, Germany, Japan, and China.

Bracco operates in more than 100 countries directly and indirectly through branches, license and distribution agreements, and joint ventures. The subsidiaries of the company are Bracco Diagnostics Inc. (the U.S. subsidiary of Bracco Imaging S.p.A.), Bracco International B.V., Acist Medical Systems, Inc. and Bracco Imaging Holding B.V.

Meticulous Research in its latest publication on Microbubbles /Ultrasound Contrast Agents Market has predicted the growth of 25.2% during the forecast year 2018-2024.

GE Healthcare

Founded in 1994 and headquartered in Illinois, U.S.; GE healthcare is a unit of General Electric Company. GE healthcare provides medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services, and services for patient care.

With its subsidiaries and strong network of distribution, the company has its presence in various regions such as North America, Europe, Asia- Pacific, Latin America, and Middle East & Africa. GE Medical Systems Healthcare Solutions, GE Healthcare Holdings, and GE Healthcare Bio-Sciences Corp. are some of the key subsidiaries of the company.

Daiichi Sankyo Company (Japan)

Founded in 1899 as Sankyo Shoten and headquartered in Tokyo, Japan; Daiichi Sankyo Company, Limited was formed through the merger of Sankyo Co., Ltd., and Daiichi Pharmaceutical Co., Ltd and is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical.

With around 100 subsidiaries and 4 associated companies, Daiichi Sankyo has strong presence across Japan, United States, Europe, Asia, and South & Central America (ASCA). The subsidiaries of the company are Daiichi Sankyo Healthcare Co., Ltd. (Japan), Daiichi Sankyo, Inc. (U.S.), and Daiichi Sankyo Europe GmbH.

nanoPET Pharma GmbH (Germany)

Founded in 2007 and headquartered in Berlin, Germany; nanoPET Pharma GmbH focuses on the R&D, production, and marketing of innovative drug substances for diagnostic imaging and consulting. The company provides ultrasound contrast agents under Viscover Imaging Agents business segment.

Authoritative Research on the Microbubbles/Ultrasound Contrast Agents Market – Global Opportunity Analysis and Industry Forecast (2018-2024)

Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:

• Recent financial performance
• Key products
• Significant company strategies
• Partnerships and acquisitions

Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.